ABSTRACT
This paper contains the reference data for the main physiological indicators of three species of laboratory animals: mice, rabbits and dogs. Data listed include the mean and the standard deviation of haematology, serum biochemistry and organ weight to body weight ratio. In addition, pathological studies including microscopical examination of organs and tissues were also done. Comparisons between sexes were analysed.
Subject(s)
Animals, Laboratory/physiology , Dogs/physiology , Mice/physiology , Rabbits/physiology , Animals , Body Weight , Female , Male , Organ Size , Reference ValuesABSTRACT
A reference database comprising body weight gain, exploratory activity, hot plate response, serum biochemistry, haematology, organ weight (%) and a complete anatomopathological study containing non-neoplastic and neoplastic lesions over 1200 Sprague-Dawley rats from 6 to 32 months is described. Comparisons between age and sex were analysed.
Subject(s)
Database Management Systems , Rats, Sprague-Dawley/physiology , Reference Standards , Animals , Exploratory Behavior , Female , Incidence , Male , Neoplasms, Experimental , Organ Size , Pain/physiopathology , Rats , Rats, Sprague-Dawley/anatomy & histology , Weight GainABSTRACT
Policosanol (trade name Ateromixol) is a new cholesterol-lowering drug that has been isolated and purified from sugar cane wax. The effects of policosanol (50-500 mg/kg) administered orally for 18 months to male and female Swiss mice were investigated. No differences in daily clinical observations, weight gain, food consumption and mortality (survival analysis) between groups were found. Histopathological study showed that the frequency of neoplastic (benign and malignant) lesions was similar in the control and policosanol-treated groups. The lesions observed were similar to the spontaneous lesions in Swiss mice reported in previous studies. As no drug-related increase in the occurrence of malignant or benign neoplasm was found, nor acceleration in tumour growth in any specific group observed, this study shows no evidence of policosanol-induced carcinogenicity in Swiss mice.
Subject(s)
Anticholesteremic Agents/toxicity , Fatty Alcohols/toxicity , Neoplasms, Experimental/chemically induced , Administration, Oral , Analysis of Variance , Animals , Anticholesteremic Agents/administration & dosage , Eating/drug effects , Fatty Alcohols/administration & dosage , Female , Heart/drug effects , Kidney/drug effects , Kidney/metabolism , Liver/drug effects , Liver/metabolism , Longitudinal Studies , Lung/drug effects , Lung/metabolism , Male , Mice , Myocardium/metabolism , Organ Size/drug effects , Spleen/drug effects , Spleen/metabolism , Survival Analysis , Thymus Gland/drug effects , Thymus Gland/metabolism , Weight Gain/drug effectsABSTRACT
Policosanol is a new chemical entity composed of 8 higher aliphatic alcohols obtained from sugar cane (Saccharum officinarum), L. wax, whose cholesterol-lowering effects have been demonstrated in experimental models, healthy volunteers and patients with type II hypercholesterolemia. This study investigated the oral toxicity of policosanol administered for 52 weeks to beagle dogs. Twenty-four beagle dogs (12 males and 12 females) were distributed randomly in 3 experimental groups (4 animals/group): a control and 2 treated groups receiving policosanol at 30 and 180 mg/kg daily (7 days/week) by gavage. No mortality was observed in any group. Overall, policosanol was well tolerated throughout the study and no toxic symptoms were observed. All groups showed similar weight gain and food consumption. Lipid profile determinations showed that policosanol decreased total cholesterol by 20% approximately from 8 to 52 weeks. Cholesterol-lowering effects did not wear off during the study, thus demonstrating the persistence of the effectiveness. Triglycerides and high density lipoprotein-cholesterol (HDL-C) were not changed significantly. No blood biochemistry or histopathological disturbances attributable to treatment were observed. This study has shown that no drug-related toxicity was induced by policosanol administered up to 180 mg/kg/day for 52 weeks to beagle dogs. Since this dose is approximately 620 times higher than the maximal recommended therapeutic dose (20 mg/day) it indicates a good safety margin of this product.
Subject(s)
Anticholesteremic Agents/toxicity , Fatty Alcohols/toxicity , Administration, Oral , Animals , Blood Chemical Analysis , Body Weight/drug effects , Dogs , Female , Lipids/blood , Male , Organ Size/drug effects , Random Allocation , Time FactorsABSTRACT
The effects of policosanol (50-500 mg/kg) administered orally for 24 months to Sprague Dawley rats of both sexes were investigated. No differences related to daily clinical observations, weight gain, food consumption, or mortality (survival analysis) between groups were found. Histopathological study showed that the frequency of the occurrence of non-neoplastic and neoplastic (benign and malignant) lesions was similar in the control and policosanol-treated groups. The lesions observed in this study were similar to the spontaneous lesions reported in this species in previous studies. Since no drug-related increase in the occurrence of malignant or benign neoplasms was found, nor acceleration in tumors growth in any specific group was observed, this study shows no evidence of policosanol induced carcinogenicity in this strain of rats.
Subject(s)
Fatty Alcohols/pharmacology , Neoplasms/chemically induced , Animals , Anticholesteremic Agents/pharmacology , Body Weight/drug effects , Carcinogenicity Tests , Female , Male , Neoplasms, Experimental/chemically induced , Rats , Rats, Sprague-Dawley , Survival AnalysisABSTRACT
Policosanol is a natural mixture of higher aliphatic primary alcohols. Oral toxicity of policosanol was evaluated in a 12-month study in which doses from 0.5 to 500 mg/kg were given orally to Sprague Dawley (SD) rats (20/sex/group) daily. There was no treatment-related toxicity. Thus, effects on body weight gain, food consumption, clinical observations, blood biochemistry, hematology, organ weight ratios and histopathological findings were similar in control and treated groups. This study supports the wide safety margin of policosanol when administered chronically.
